ES2168312T3 - Utilizacion de angiotensina iii y sus analogos para la reparacion tisular. - Google Patents

Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.

Info

Publication number
ES2168312T3
ES2168312T3 ES94928150T ES94928150T ES2168312T3 ES 2168312 T3 ES2168312 T3 ES 2168312T3 ES 94928150 T ES94928150 T ES 94928150T ES 94928150 T ES94928150 T ES 94928150T ES 2168312 T3 ES2168312 T3 ES 2168312T3
Authority
ES
Spain
Prior art keywords
analogs
tissular
repair
angiotensin iii
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94928150T
Other languages
English (en)
Inventor
Kathleen Elizabeth Rodgers
Gere Stodder Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2168312T3 publication Critical patent/ES2168312T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ANGIOTENSINA III Y ANALOGOS DE LA MISMA SON UTILES EN LA ACELERACION DE CICATRIZACION DE HERIDAS. ESTOS ANALOGOS FORMAN LA BASE DE COMPOSICIONES UTILES PARA ACELERAR LA CICATRIZACION DE HERIDAS, EN LAS QUE EL AGENTE ACTIVO ESTA PRESENTE EN UNA CANTIDAD EFECTIVA PARA ACELERAR LA CICATRIZACION DE HERIDAS. PREFERIBLEMENTE, LAS COMPOSICIONES ESTAN EN FORMA DE SOLUCIONES MATRICALES O MICELARES.
ES94928150T 1993-09-24 1994-09-19 Utilizacion de angiotensina iii y sus analogos para la reparacion tisular. Expired - Lifetime ES2168312T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12636893A 1993-09-24 1993-09-24

Publications (1)

Publication Number Publication Date
ES2168312T3 true ES2168312T3 (es) 2002-06-16

Family

ID=22424455

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94928150T Expired - Lifetime ES2168312T3 (es) 1993-09-24 1994-09-19 Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.

Country Status (13)

Country Link
US (1) US5629292A (es)
EP (1) EP0730465B1 (es)
JP (1) JPH09502977A (es)
AT (1) ATE210677T1 (es)
AU (1) AU706333B2 (es)
CA (1) CA2172493C (es)
DE (1) DE69429450T2 (es)
DK (1) DK0730465T3 (es)
ES (1) ES2168312T3 (es)
PT (1) PT730465E (es)
TW (1) TW311088B (es)
WO (1) WO1995008337A1 (es)
ZA (1) ZA947338B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
AU758319B2 (en) * 1994-11-14 2003-03-20 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
MY121607A (en) * 1995-07-10 2006-02-28 Hyundai Curitel Inc Grid moving method of object image and apparatus using the same and compaction/motion estimation method using the same and apparatus thereof
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
EP1410801B1 (en) 1997-01-28 2013-04-10 University Of Southern California Method for promoting hematopoietic cell proliferation and differentiation
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
AU6650098A (en) * 1997-02-04 1998-08-25 University Of Southern California Method for accelerating healing of thermal injuries
US6197751B1 (en) 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
EP1047441A1 (en) * 1997-11-26 2000-11-02 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
AU755225B2 (en) 1997-12-12 2002-12-05 University Of Southern California Wound healing compositions
CA2319701C (en) * 1998-02-09 2009-09-29 University Of Southern California Method of promoting erythropoiesis
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
WO1999046285A2 (en) 1998-03-11 1999-09-16 University Of Southern California Method of promoting production of living tissue equivalents
EP1067952A1 (en) * 1998-04-09 2001-01-17 University Of Southern California Methods for treatment and prevention of infections
JP2003521441A (ja) 1998-05-11 2003-07-15 ユニヴァースティ オブ サザーン カリフォルニア 化学療法後の白血球生残率を増加させる方法
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6916783B2 (en) * 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
DE69911609T2 (de) 1998-07-13 2004-07-01 University Of Southern California, Los Angeles Verfahren zur beschleunigen den zuwachs und heilen von knochen und knorpel
CA2339330A1 (en) * 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
DE60017211T2 (de) 1999-02-17 2005-06-02 Pfizer Products Inc., Groton Fusionsproteine mit Trägern welche eine doppelte Immunantwort induzieren
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
DE60142632D1 (de) * 2000-11-30 2010-09-02 Novodermix Internat Ltd Heilung von wunden
AU2002308522A1 (en) * 2001-05-01 2002-11-11 University Of Southern California Methods for inhibiting tumor cell proliferation
KR20100061677A (ko) * 2007-09-11 2010-06-08 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｔｙｒ-ｗ-ｍｉｆ-1 및 유로코르틴 2의 용도
EP2185180A1 (en) * 2007-09-11 2010-05-19 Mondobiotech Laboratories AG Big gastrin i as a therapeutic agent
JP2010538994A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 例えば肺炎連鎖球菌感染症を治療するためのｂｆｇｆ１−２４および任意での（ａｒｇ８）バソプレシンの使用
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008303869A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide RFMWMR as a therapeutic agent
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
PT2376101E (pt) 2008-12-29 2016-02-04 Trevena Inc Efectores da beta-arrestina e composições e métodos para a sua utilização
CN102858360B (zh) 2011-02-02 2017-07-25 南加利福尼亚大学 治疗糖尿病足溃疡的方法
CN104168907A (zh) 2012-01-31 2014-11-26 特维娜有限公司 β-抑制蛋白效应器及其组合物与使用方法
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
JP6254692B2 (ja) 2013-07-03 2017-12-27 ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ 認知機能不全を治療するための方法
EP3102223A4 (en) 2014-02-07 2017-11-29 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors
US9796759B2 (en) 2014-07-21 2017-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
WO2017066552A1 (en) * 2015-10-14 2017-04-20 Tarix Pharmaceuticals Ltd. Methods and compositions for the treatment of epidermolysis bullosa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886134A (en) * 1970-03-09 1975-05-27 Morton Norwich Products Inc Analogues of angiotensin II
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair

Also Published As

Publication number Publication date
WO1995008337A1 (en) 1995-03-30
CA2172493C (en) 2003-09-16
DE69429450T2 (de) 2002-07-25
JPH09502977A (ja) 1997-03-25
DK0730465T3 (da) 2002-04-08
EP0730465A1 (en) 1996-09-11
ATE210677T1 (de) 2001-12-15
AU7730294A (en) 1995-04-10
DE69429450D1 (de) 2002-01-24
PT730465E (pt) 2002-06-28
EP0730465A4 (en) 1997-11-12
EP0730465B1 (en) 2001-12-12
US5629292A (en) 1997-05-13
ZA947338B (en) 1995-05-10
AU706333B2 (en) 1999-06-17
TW311088B (es) 1997-07-21
CA2172493A1 (en) 1995-03-30

Similar Documents

Publication Publication Date Title
ES2168312T3 (es) Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.
DE69435301D1 (de) Verwendung von Angiotensin-II-Analogen zur Gewebewiederherstellung
MX9703609A (es) Uso de fragmentos de angiotensina ii y analogos de la misma para la preparacion de composiciones en la preparacion de tejido.
BRPI0513460A (pt) composição aquosa suave apropriada para a limpeza do cabelo e da pele
GT199600026A (es) Isotiazolonas
CY1106064T1 (el) Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση
ES2110003T3 (es) Nuevas composiciones a base de derivados de la clase de los taxanos.
PE30298A1 (es) Inhibidores de metaloproteasas de matriz
CY1111100T1 (el) Καλλυντικη συνθεση για τη θεραπεια γηρασμενου και/ή στρεσαρισμενου δερματος
PE27891A1 (es) Metodo y composicion para humectar tejidos
AR004026A1 (es) Procedimiento de tintura por oxidacion de las fibras queratinicas, una composicion tintorea empleada en dicho procedimiento y dispositivo de varioscompartimentos que comprende la composicion tintorea y la composicion oxidante empleadas en dicho procedimiento.
ES2155874T3 (es) Composiciones cosmeticas que contienen acido betulinico.
BRPI0413588A (pt) sistema de branqueamento de dentes, método de branqueamento da superfìcie de um dente, e, kit de branqueamento de dentes
AR045748A1 (es) Metodo para alargar el cabello con composiciones que comprenden un alfa-hidroxiacido y un agente de reduccion
MX9305354A (es) Detergente liquido o en forma de gel para el lavado de vajilla que contiene alquil etoxi carboxilato, iones divalentes y alquilpolietoxipolicarboxilato.
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
BR0117149A (pt) Uso de um copolìmero para produzir uma forma farmacêutica contendo um peptìdio ou proteìna como agente ativo
ES2082894T3 (es) Dihidropirido(4,3-d)pirimidinas 4-sustituidas como analgesicos y agentes antiinflamatorios topicos para el tratamiento de enfermedades de la piel.
ES2159013T3 (es) Forma farmaceutica para la liberacion de colagenasa en heridas y procedimiento para su elaboracion.
ES2129135T3 (es) Composiciones limpiadoras que contienen un alcanoato como acondicionador.
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
BR0011980A (pt) Composiçao cosmética; e uso de uma composição
BR0213156A (pt) Formas cristalinas anidras de gabapentina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730465

Country of ref document: ES